<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>260321</rcn>
  <id>101158879</id>
  <acronym>Penphomet</acronym>
  <teaser>Adoptive cell therapy has emerged as a promising strategy to treat cancer. It relies on patient-derived cells, such as T cells and mesenchymal stromal cells (MSCs), which are genetically engineered to become better equipped to fight cancer cells. While ex vivo genetic...</teaser>
  <objective>Adoptive cell therapy has emerged as a promising strategy to treat cancer. It relies on patient-derived cells, such as T cells and mesenchymal stromal cells (MSCs), which are genetically engineered to become better equipped to fight cancer cells. While ex vivo genetic modification of T cells and MSCs has traditionally been performed with viral vectors, they come with concerns about safety, sustainable production and high development costs. Electroporation is a non-viral alternative transfection technology, but can lead to significant gene expression changes, phenotypic alterations, and decreased therapeutic potency. Recently, photoporation with electrospun photothermal nanofibers (PEN photoporation) was demonstrated to provide a safer alternative with minimal impact on the cell’s functionality and phenotype. The technology makes use of photothermal nanofibers which, upon stimulation with laser light, can transiently permeabilize cells to allow gene-modifying effector molecules to enter the cells. Having been thoroughly demonstrated and validated in a research setting (TRL4), this project aims to bring the PEN photoporation technology to TLR6 by developing hard- and software for automated high-throughput transfections of T cells (&gt;1B cells/h) and MSCs (&gt;10M cells/h). The technology will be extensively tested and validated in the cGMP compliant laboratories of the project partners for the genetic engineering of T cells and MSCs. At the same time, steps will be taken to prepare for commercialization and market deployment. By the end of the project a fully automated and validated high-throughput prototype system will be available for installation at centralized cell production facilities or ready for integration in point-of-care cell manufacturing equipment. This project aligns with the Micro-Nano-Bio challenge as it combines nanotechnology with microfluidics to enhance genetically engineered cell therapy products.</objective>
  <title>PEN photoporation for the genetic engineering of therapeutic mesenchymal stromal cells and T cells</title>
  <totalCost>2497711.25</totalCost>
  <ecMaxContribution>2497711.25</ecMaxContribution>
  <startDate>2024-03-01</startDate>
  <endDate>2027-02-28</endDate>
  <ecSignatureDate>2024-02-26</ecSignatureDate>
  <duration>36</duration>
  <status>SIGNED</status>
  <keywords>cell therapy, nanotechnology, microfluidics, automation, cell transfection, genetic engineering, CAR T, mesenchymal stromal cells</keywords>
  <identifiers>
    <grantDoi>10.3030/101158879</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-10-20 17:38:03</sourceUpdateDate>
  <contentCreationDate>2024-03-04 13:39:43</contentCreationDate>
  <contentUpdateDate>2025-10-28 14:07:00</contentUpdateDate>
  <lastUpdateDate>2025-11-03 09:43:36</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>453103</rcn>
        <id>453103-advanced-photoporation-technology-for-high-throughput-cell-therapy</id>
        <title>Advanced photoporation technology for high-throughput cell therapy</title>
        <contentUpdateDate>2024-12-05 17:04:51</contentUpdateDate>
        <relations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode>/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55876</rcn>
        <title>HORIZON-EIC-2023-TRANSITION-01</title>
        <identifier>HORIZON-EIC-2023-TRANSITION-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55876</rcn>
        <title>HORIZON-EIC-2023-TRANSITION-01</title>
        <identifier>HORIZON-EIC-2023-TRANSITION-01</identifier>
      </call>
      <organization netEcContribution="1930211.25" totalCost="1930211.25" source="corda" order="1" ecContribution="1930211.25" terminated="false" sme="true" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1987220</rcn>
        <id>881957175</id>
        <vatNumber>BE0774374358</vatNumber>
        <legalName>TRINCE</legalName>
        <address>
          <street>OTTERGEMSESTEENWEG ZUID 731</street>
          <city>GENT</city>
          <postalCode>9000</postalCode>
          <country>BE</country>
          <geolocation>51.0192984,3.7398955</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Arr. Gent</name>
              <rcn>188227780</rcn>
              <nutsCode>BE234</nutsCode>
              <parents>
                <region>
                  <name>Prov. Oost-Vlaanderen</name>
                  <rcn>188227816</rcn>
                  <nutsCode>BE23</nutsCode>
                  <parents>
                    <region>
                      <name>Vlaams Gewest</name>
                      <rcn>188230184</rcn>
                      <nutsCode>BE2</nutsCode>
                      <parents>
                        <region>
                          <name>Belgium</name>
                          <rcn>188385832</rcn>
                          <nutsCode>BE</nutsCode>
                          <euCode>BE</euCode>
                          <isoCode>BE</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Belgium</name>
              <rcn>188385832</rcn>
              <nutsCode>BE</nutsCode>
              <euCode>BE</euCode>
              <isoCode>BE</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <organization netEcContribution="250000" totalCost="250000" source="corda" order="3" ecContribution="250000" terminated="false" sme="false" type="participant">
        <availableLanguages>en</availableLanguages>
        <rcn>2394075</rcn>
        <id>951404713</id>
        <vatNumber>ESG42152405</vatNumber>
        <legalName>FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON</legalName>
        <shortName>IECSCYL</shortName>
        <address>
          <street>PARQUE SANTA CLARA</street>
          <city>Soria</city>
          <postalCode>42002</postalCode>
          <country>ES</country>
          <geolocation>41.7633842,-2.464204</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/REC</code>
              <title>Research Organisations</title>
              <displayCode>/Research Organisations</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Soria</name>
              <rcn>242237511</rcn>
              <nutsCode>ES417</nutsCode>
              <parents>
                <region>
                  <name>Castilla y León</name>
                  <rcn>242237544</rcn>
                  <nutsCode>ES41</nutsCode>
                  <parents>
                    <region>
                      <name>Centro (ES)</name>
                      <rcn>1465448</rcn>
                      <nutsCode>ES4</nutsCode>
                      <parents>
                        <region>
                          <name>Spain</name>
                          <rcn>242387496</rcn>
                          <nutsCode>ES</nutsCode>
                          <euCode>ES</euCode>
                          <isoCode>ES</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Spain</name>
              <rcn>242387496</rcn>
              <nutsCode>ES</nutsCode>
              <euCode>ES</euCode>
              <isoCode>ES</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <organization netEcContribution="317500" totalCost="317500" source="corda" order="2" ecContribution="317500" terminated="false" sme="false" type="participant">
        <availableLanguages>en</availableLanguages>
        <rcn>1975800</rcn>
        <id>889158843</id>
        <vatNumber>NL860812418B01</vatNumber>
        <legalName>NETHERLANDS CENTER FOR THE CLINICAL ADVANCEMENT OF STEM CELL &amp; GENE THERAPIES BV</legalName>
        <shortName>NECSTGEN BV</shortName>
        <address>
          <street>SYLVIUSWEG 62</street>
          <city>LEIDEN</city>
          <postalCode>2333 BE</postalCode>
          <country>NL</country>
          <geolocation>52.1668723,4.4646258</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <rcn>1471676</rcn>
              <nutsCode>NL363</nutsCode>
            </region>
            <region type="relatedRegion">
              <name>Netherlands</name>
              <rcn>391547432</rcn>
              <nutsCode>NL</nutsCode>
              <euCode>NL</euCode>
              <isoCode>NL</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>707287</rcn>
        <id>HORIZON_HORIZON-EIC-2023-TRANSITIONCHALLENGES-01</id>
        <code>HORIZON-EIC-2023-TRANSITIONCHALLENGES-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Transition Challenge: Full scale Micro-Nano-Bio devices for medical and medical research applications</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1359109</rcn>
        <id>101158879_21_DELIVHORIZON</id>
        <title>Project website and logo</title>
        <description>Ensure the website and project logo is scheduled at month 2 (M2) and continuously updated thereafter. It is a good practice to relate the web site address to the title of the project and to have the address in the .eu domain.</description>
        <sourceUpdateDate>2025-10-20 17:42:54</sourceUpdateDate>
        <contentUpdateDate>2025-10-28 18:30:41</contentUpdateDate>
        <relations>
          <associations>
            <webLink source="corda" type="projectDeliverable">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <id>06619611626dff76007d334ffc199061</id>
              <physUrl>https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e50be30c79&amp;appId=PPGMS</physUrl>
              <defaultLanguage>en</defaultLanguage>
            </webLink>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/deliverable</code>
              <title>Project deliverable</title>
              <description>Result: Project deliverables</description>
              <displayCode>/Project deliverable</displayCode>
            </category>
            <category classification="deliverableType" type="isDeliveredAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/DEC</code>
              <title>Websites, patent fillings, videos etc.</title>
              <displayCode>/Websites, patent fillings, videos etc.</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1363187</rcn>
        <id>101158879_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - Penphomet (PEN photoporation for the genetic engineering of therapeutic mesenchymal stromal cells and T cells)</title>
        <description>periodic</description>
        <teaser>Adoptive cell therapy has emerged as a promising strategy to treat cancer. It relies on patient-derived cells, such as T cells and mesenchymal stromal cells (MSCs), which are genetically engineered to become better equipped to fight cancer cells. While ex vivo genetic...</teaser>
        <sourceUpdateDate>2025-10-20 17:42:54</sourceUpdateDate>
        <contentUpdateDate>2025-10-27 16:43:15</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/25/69</code>
        <title>nanotechnology</title>
        <displayCode>/engineering and technology/nanotechnology</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-EIC</code>
        <title>HORIZON EIC Grants</title>
        <description>HORIZON EIC Grants</description>
        <displayCode>/HORIZON EIC Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>